soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Reduces CV Events in T2DM β (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine π§ͺ T2DM + ASCVD/CKD π Oral semaglutide 14 mg vs placebo π Clinical Effectiveness and Safety of
Description
Vaxess Technologies rebrands as Terrestrial Bio, raises $50M to pivot from vaccines to GLP-1 patches for semaglutide delivery, after AstraZeneca partnership ends.
With the recent announcement that the shortage of Ozempic and Wegovy is officially over, the FDA has declared that compounding pharmacies must stop producing and selling compounded semaglutide by May 22, 2025
GLP-1 receptor agonist weight loss injections in Boston can help you safely lose weight and keep it off
It belongs to a class of drugs known as GLP-1 receptor agonists, which work by increasing insulin production and reducing the release of glucose from the liver
But what most patients dont realize is that these medications can ha
Researchers are examining whether drugs currently approved to treat obesity and type 2 diabetes could be useful for a wider range of health challenges.
